Patient Linda Dzobiak (left) with Christin Whalen, RN, BSN, OCN
Researchers in the Gynecologic Oncology Program are exploring gynecologic cancers from a wide variety of scientific angles – from discoveries about the genes that cause tumors to develop and grow, to investigations of immunotherapies, to studies of ways drugs can be combined to
fight recurrent cancer.
Our basic scientists are looking at immune response through laboratory studies, creating laboratory models to study cancer resistance, and researching how to exploit DNA repair defects. They are also exploring the genetic underpinnings of gynecologic cancers to find the
mutations responsible for the disease. Our physician-scientists are focused on the development of new treatments for specific subtypes of gynecologic cancers, including PARP inhibitors for BRCA-related high grade serous ovarian cancer.
As a major research institution, Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) provides patients not only with outstanding care, but also with some of the most advanced therapies available.
We base our treatments on the latest scientific findings, and many patients have the opportunity to participate in clinical trials of promising new treatments.
Appointments and Second Opinions